$RCUS
Arcus Biosciences, Inc.

2020 Q2 Form 10-Q Financial Statement

#000156459020037782 Filed on August 06, 2020

View on sec.gov

Income Statement

Concept 2020 Q2 2019 Q2
Revenue $1.750M $1.750M
YoY Change 0.0% 40.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $11.43M $5.910M
YoY Change 93.4% 71.3%
% of Gross Profit
Research & Development $35.69M $25.00M
YoY Change 42.78% 82.49%
% of Gross Profit
Depreciation & Amortization $800.0K $800.0K
YoY Change 0.0% -11.11%
% of Gross Profit
Operating Expenses $47.13M $30.91M
YoY Change 52.46% 80.24%
Operating Profit -$45.38M -$29.16M
YoY Change 55.61% 83.41%
Interest Expense $300.0K $1.070M
YoY Change -71.96% -54.85%
% of Operating Profit
Other Income/Expense, Net $301.0K $1.070M
YoY Change -71.87% -54.78%
Pretax Income -$45.07M -$28.09M
YoY Change 60.45% 107.61%
Income Tax
% Of Pretax Income
Net Earnings -$45.07M -$28.09M
YoY Change 60.46% 107.57%
Net Earnings / Revenue -2575.66% -1605.14%
Basic Earnings Per Share
Diluted Earnings Per Share -$928.1K -$641.3K
COMMON SHARES
Basic Shares Outstanding 48.56M 45.41M
Diluted Shares Outstanding 48.56M

Balance Sheet

Concept 2020 Q2 2019 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $462.5M $224.4M
YoY Change 106.11% -15.54%
Cash & Equivalents $285.2M $76.07M
Short-Term Investments $177.3M $148.3M
Other Short-Term Assets $8.700M $3.300M
YoY Change 163.64% 106.25%
Inventory
Prepaid Expenses
Receivables $500.0K
Other Receivables $0.00
Total Short-Term Assets $471.6M $227.7M
YoY Change 107.08% -14.85%
LONG-TERM ASSETS
Property, Plant & Equipment $8.264M $10.36M
YoY Change -20.25% -17.19%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $357.0K
YoY Change -79.14%
Other Assets $1.323M $319.0K
YoY Change 314.73% 55.61%
Total Long-Term Assets $9.790M $11.24M
YoY Change -12.91% -57.46%
TOTAL ASSETS
Total Short-Term Assets $471.6M $227.7M
Total Long-Term Assets $9.790M $11.24M
Total Assets $481.4M $239.0M
YoY Change 101.44% -18.68%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $12.05M $2.448M
YoY Change 392.32% -54.57%
Accrued Expenses $5.611M $15.55M
YoY Change -63.92% 258.18%
Deferred Revenue $7.000M $7.000M
YoY Change 0.0%
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $40.03M $26.51M
YoY Change 50.96% 61.86%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $693.0K $1.283M
YoY Change -45.99% -44.41%
Total Long-Term Liabilities $693.0K $1.283M
YoY Change -45.99% -44.41%
TOTAL LIABILITIES
Total Short-Term Liabilities $40.03M $26.51M
Total Long-Term Liabilities $693.0K $1.283M
Total Liabilities $52.68M $42.33M
YoY Change 24.45% 7.73%
SHAREHOLDERS EQUITY
Retained Earnings -$278.2M -$166.4M
YoY Change 67.18% 66.84%
Common Stock $6.000K $4.000K
YoY Change 50.0% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $428.7M $196.6M
YoY Change
Total Liabilities & Shareholders Equity $481.4M $239.0M
YoY Change 101.44% -18.68%

Cashflow Statement

Concept 2020 Q2 2019 Q2
OPERATING ACTIVITIES
Net Income -$45.07M -$28.09M
YoY Change 60.46% 107.57%
Depreciation, Depletion And Amortization $800.0K $800.0K
YoY Change 0.0% -11.11%
Cash From Operating Activities -$23.90M -$19.80M
YoY Change 20.71% 81.65%
INVESTING ACTIVITIES
Capital Expenditures -$300.0K -$600.0K
YoY Change -50.0% -53.85%
Acquisitions
YoY Change
Other Investing Activities -$86.90M $27.20M
YoY Change -419.49% -282.55%
Cash From Investing Activities -$87.10M $26.70M
YoY Change -426.22% -265.84%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 328.9M 600.0K
YoY Change 54716.67% -154.55%
NET CHANGE
Cash From Operating Activities -23.90M -19.80M
Cash From Investing Activities -87.10M 26.70M
Cash From Financing Activities 328.9M 600.0K
Net Change In Cash 217.9M 7.500M
YoY Change 2805.33% -126.69%
FREE CASH FLOW
Cash From Operating Activities -$23.90M -$19.80M
Capital Expenditures -$300.0K -$600.0K
Free Cash Flow -$23.60M -$19.20M
YoY Change 22.92% 100.0%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
us-gaap Profit Loss
ProfitLoss
-72827000
CY2020Q2 us-gaap Lessee Operating Lease Existence Of Option To Extend
LesseeOperatingLeaseExistenceOfOptionToExtend
true
CY2020Q2 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P8Y
CY2020Q2 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:LicenseAndServiceMember
CY2020Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
8264000
CY2020Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
203000
CY2020Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1323000
CY2020Q2 us-gaap Assets
Assets
481389000
CY2020Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
12052000
CY2020Q2 rcus Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
13899000
CY2020Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5611000
CY2020Q2 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
7000000
CY2020Q2 us-gaap Assets Current
AssetsCurrent
471599000
CY2020Q2 us-gaap Interest Receivable Current
InterestReceivableCurrent
239000
CY2020Q2 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
222000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
9330000
CY2019Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
67000
dei Document Transition Report
DocumentTransitionReport
false
dei Security12b Title
Security12bTitle
Common Stock, Par Value $0.0001 Per Share
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
57937000
dei Security Exchange Name
SecurityExchangeName
NYSE
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2019Q4 us-gaap Interest Receivable Current
InterestReceivableCurrent
251000
CY2019Q4 us-gaap Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
130333000
CY2019Q4 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
132000
dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2019Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
203000
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
21629000
CY2020Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
285185000
CY2020Q2 us-gaap Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
177288000
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
872000
CY2019Q4 us-gaap Assets
Assets
203110000
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
4704000
CY2019Q4 rcus Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
4572000
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2019Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
7000000
CY2019Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
12022000
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
400000000
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
45925004
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
45925004
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
4000
CY2019Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
369100000
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-205326000
CY2019Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
64000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
163842000
us-gaap Gain Loss On Sale Of Equity Investments
GainLossOnSaleOfEquityInvestments
613000
CY2020Q2 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-131000
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
203110000
CY2019Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1750000
CY2019Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5911000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10879000
CY2019Q2 us-gaap Operating Expenses
OperatingExpenses
30910000
CY2019Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-29160000
rcus Interest And Other Income Expense Nonoperating Net
InterestAndOtherIncomeExpenseNonoperatingNet
948000
rcus Interest And Other Income Expense Nonoperating Net
InterestAndOtherIncomeExpenseNonoperatingNet
3016000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
3500000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
3500000
CY2019Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
24999000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
40553000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
18440000
us-gaap Operating Expenses
OperatingExpenses
51432000
us-gaap Operating Income Loss
OperatingIncomeLoss
-73775000
CY2019Q2 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-412000
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-613000
CY2020Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
301000
CY2019Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1070000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
948000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-45074000
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-28090000
us-gaap Net Income Loss
NetIncomeLoss
-72827000
CY2020Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-144000
CY2019Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
84000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
80000
CY2020Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-45218000
CY2019Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-28006000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-72747000
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4470000
CY2020Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-144000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-45074000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
428710000
CY2020Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1463000
CY2020Q2 us-gaap Liabilities Current
LiabilitiesCurrent
40025000
CY2020Q2 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
8522000
CY2020Q2 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
3439000
CY2020Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
693000
CY2020Q2 us-gaap Liabilities
Liabilities
52679000
CY2020Q2 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2020Q2 us-gaap Common Stock Value
CommonStockValue
6000
CY2020Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
706713000
CY2020Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-278153000
CY2020Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
144000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
428710000
CY2020Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
481389000
CY2020Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1750000
CY2020Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11432000
CY2020Q2 us-gaap Operating Expenses
OperatingExpenses
47125000
CY2020Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-45375000
us-gaap Operating Income Loss
OperatingIncomeLoss
-47932000
CY2020Q2 rcus Interest And Other Income Expense Nonoperating Net
InterestAndOtherIncomeExpenseNonoperatingNet
301000
CY2019Q2 rcus Interest And Other Income Expense Nonoperating Net
InterestAndOtherIncomeExpenseNonoperatingNet
1482000
CY2020Q2 us-gaap Gain Loss On Sale Of Equity Investments
GainLossOnSaleOfEquityInvestments
131000
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-844000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2172000
us-gaap Net Income Loss
NetIncomeLoss
-45760000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
220000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-45540000
CY2020Q2 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.93
CY2019Q2 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.64
us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-1.57
us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-1.05
CY2020Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
48556843
CY2019Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
43797718
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
46419724
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
43653325
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
234942000
CY2019Q1 rcus Stock Issued During Period Value Vesting Of Early Exercised Stock Options And Restricted Stock
StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptionsAndRestrictedStock
273000
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1674000
CY2019Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
136000
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-17670000
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
221567000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
58835000
us-gaap Operating Expenses
OperatingExpenses
77275000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
163842000
CY2019Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
99000
CY2019Q2 rcus Stock Issued During Period Value Vesting Of Early Exercised Stock Options And Restricted Stock
StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptionsAndRestrictedStock
260000
CY2019Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
596000
CY2019Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2130000
CY2020Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
326246000
CY2019Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
84000
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-28090000
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
196646000
CY2020Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
607000
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
643000
CY2020Q1 rcus Stock Issued During Period Value Vesting Of Early Exercised Stock Options And Restricted Stock
StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptionsAndRestrictedStock
220000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3462000
CY2020Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
224000
CY2020Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1751000
CY2020Q2 rcus Stock Issued During Period Value Vesting Of Early Exercised Stock Options And Restricted Stock
StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptionsAndRestrictedStock
216000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-27753000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
140638000
us-gaap Profit Loss
ProfitLoss
-45760000
us-gaap Share Based Compensation
ShareBasedCompensation
7932000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-36592000
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
139689000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
323000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
1580000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
661000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-565000
us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
29000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-3500000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-3500000
rcus Increase Decrease In Deferred Rent
IncreaseDecreaseInDeferredRent
-266000
rcus Increase Decrease In Deferred Rent
IncreaseDecreaseInDeferredRent
-262000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
310000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-55215000
us-gaap Share Based Compensation
ShareBasedCompensation
3804000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
1629000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
1836000
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-613000
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-844000
us-gaap Gain Loss On Sale Of Equity Investments
GainLossOnSaleOfEquityInvestments
613000
us-gaap Increase Decrease In Contract With Customer Asset
IncreaseDecreaseInContractWithCustomerAsset
90000
us-gaap Increase Decrease In Due From Related Parties Current
IncreaseDecreaseInDueFromRelatedPartiesCurrent
-21000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
4601000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
952000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
135000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
35000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
6668000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-566000
rcus Increase Decrease In Accrued Research And Development Expenses
IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses
9327000
rcus Increase Decrease In Accrued Research And Development Expenses
IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses
10094000
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
123837000
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
92134000
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
165968000
us-gaap Proceeds From Sale Of Short Term Investments
ProceedsFromSaleOfShortTermInvestments
1003000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
465000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1179000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-47017000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
40952000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
326512000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
3001000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
695000
rcus Repurchase Of Unvested Shares Of Stock
RepurchaseOfUnvestedSharesOfStock
33000
rcus Repurchase Of Unvested Shares Of Stock
RepurchaseOfUnvestedSharesOfStock
51000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
329480000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
644000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
227248000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
5004000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
58140000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
71267000
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
285388000
CY2019Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
76271000
rcus Unpaid Portion Of Financing Costs Included In Accounts Payable
UnpaidPortionOfFinancingCostsIncludedInAccountsPayable
266000
rcus Unpaid Portion Of Deferred Financing Costs Included In Accounts Payable
UnpaidPortionOfDeferredFinancingCostsIncludedInAccountsPayable
316000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
110000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
48000
rcus Vesting Of Early Exercised Stock Options And Restricted Stock
VestingOfEarlyExercisedStockOptionsAndRestrictedStock
436000
rcus Vesting Of Early Exercised Stock Options And Restricted Stock
VestingOfEarlyExercisedStockOptionsAndRestrictedStock
533000
us-gaap Nature Of Operations
NatureOfOperations
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Note </span><span style="color:#000000;">1. </span>Organization </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Description of Business </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Arcus Biosciences, Inc. (the Company) is a clinical-stage biopharmaceutical company focused on creating best-in-class cancer therapies. The Company’s initial focus has been on well-characterized biological pathways with significant scientific data supporting their importance. Since its inception in 2015, the Company has built a robust and highly efficient drug discovery capability to create highly differentiated small molecules, which the Company is developing in combination with its in-licensed monoclonal antibodies through rationally designed, indication-specific, adaptive clinical trial designs. </p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Liquidity and Capital Resources</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of June 30, 2020, the Company had cash and investments of $462.5 million, which are cash, cash equivalents, and investments in marketable securities, which the Company believes will be sufficient to fund its planned operations for a period of at least twelve months following the filing date of this report.</p>
us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of the Company’s condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, as well as related disclosures of contingent assets and liabilities. Estimates were used to determine the value of stock-based awards and other issuances, accruals for research and development costs, useful lives of long-lived assets, and uncertain tax positions. Actual results could differ materially from the Company’s estimates. </p>
CY2020Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
285185000
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
57937000
CY2020Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
203000
CY2019Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
203000
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
285388000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
58140000
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Concentration of Credit Risk</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents, short-term and long-term investments are financial instruments that potentially subject the Company to concentrations of credit risk. The Company invests in money market funds, treasury bills and notes, government bonds, commercial paper and corporate notes. The Company limits its credit risk associated with cash equivalents, short-term and long-term investments by placing them with banks and institutions it believes are credit worthy and in highly rated investments. </p>
CY2020Q2 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2019Q4 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2020Q2 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2019Q4 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2020Q2 us-gaap Fair Value Liabilities Level1 To Level2 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2TransfersAmount
0
CY2019Q4 us-gaap Fair Value Liabilities Level1 To Level2 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2TransfersAmount
0
CY2020Q2 us-gaap Fair Value Liabilities Level2 To Level1 Transfers Amount
FairValueLiabilitiesLevel2ToLevel1TransfersAmount
0
CY2019Q4 us-gaap Fair Value Liabilities Level2 To Level1 Transfers Amount
FairValueLiabilitiesLevel2ToLevel1TransfersAmount
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0
CY2019 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0
CY2019 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
0
CY2019 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
0
CY2019 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
0
CY2020Q2 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
285185000
CY2019Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
57937000
CY2020Q2 us-gaap Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
177288000
CY2019Q4 us-gaap Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
130333000
CY2020Q2 rcus Cash Cash Equivalents And Available For Sale Investments
CashCashEquivalentsAndAvailableForSaleInvestments
462473000
CY2019Q4 rcus Cash Cash Equivalents And Available For Sale Investments
CashCashEquivalentsAndAvailableForSaleInvestments
188270000
CY2019 us-gaap Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
0
us-gaap Reclassification From Accumulated Other Comprehensive Income Current Period Net Of Tax
ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
0
CY2020Q2 us-gaap Available For Sale Securities
AvailableForSaleSecurities
462473000
CY2019 us-gaap Reclassification From Accumulated Other Comprehensive Income Current Period Net Of Tax
ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
0
CY2020Q2 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
462329000
CY2020Q2 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
151000
CY2020Q2 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
7000
CY2019Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
188206000
CY2019Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
3000
CY2019Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
188270000
CY2020Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3980000
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4571000
CY2020Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
437000
CY2019Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
183000
CY2020Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1194000
CY2019Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
196000
CY2020Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5611000
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4950000
CY2020Q2 us-gaap Deferred Revenue Revenue Recognized1
DeferredRevenueRevenueRecognized1
1750000
CY2019Q2 us-gaap Deferred Revenue Revenue Recognized1
DeferredRevenueRevenueRecognized1
1750000
us-gaap Deferred Revenue Revenue Recognized1
DeferredRevenueRevenueRecognized1
3500000
us-gaap Deferred Revenue Revenue Recognized1
DeferredRevenueRevenueRecognized1
3500000
CY2020Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4470000
CY2019Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2130000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7932000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3804000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-45074000
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-28090000
us-gaap Net Income Loss
NetIncomeLoss
-72827000
us-gaap Net Income Loss
NetIncomeLoss
-45760000
CY2020Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
50153160
CY2019Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
45409588
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
48053186
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
44970831
CY2020Q2 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
1596317
CY2019Q2 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
1611870
us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
1633462
us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
1317506
CY2020Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
48556843
CY2019Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
43797718
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
46419724
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
43653325
CY2020Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.93
CY2019Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.64
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.57
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.05
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9429282
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6372642
rcus Operating Lease Expiration Year
OperatingLeaseExpirationYear
2025
CY2020Q2 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
10100000
CY2020Q2 us-gaap Lessee Operating Lease Option To Extend
LesseeOperatingLeaseOptionToExtend
eight-year

Files In Submission

Name View Source Status
0001564590-20-037782-index-headers.html Edgar Link pending
0001564590-20-037782-index.html Edgar Link pending
0001564590-20-037782.txt Edgar Link pending
0001564590-20-037782-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
ghmvlagrgixq000001.jpg Edgar Link pending
ghmvlagrgixq000002.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
rcus-10q_20200630.htm Edgar Link pending
rcus-10q_20200630_htm.xml Edgar Link completed
rcus-20200630.xsd Edgar Link pending
rcus-20200630_cal.xml Edgar Link unprocessable
rcus-20200630_def.xml Edgar Link unprocessable
rcus-20200630_lab.xml Edgar Link unprocessable
rcus-20200630_pre.xml Edgar Link unprocessable
rcus-ex101_386.htm Edgar Link pending
rcus-ex104_320.htm Edgar Link pending
rcus-ex311_6.htm Edgar Link pending
rcus-ex312_7.htm Edgar Link pending
rcus-ex321_9.htm Edgar Link pending
rcus-ex322_8.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending